45 бет - Әлемдегі ең жақсы дәрігерлер

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

2017: Oticon Medical Scientific Center Copenhagen Denmark.
2016: ICLO Teaching Center New Endoscopic Approaches to Lateral Skull Base, Inner Ear and Cerebello-Pontine Angle, Verona Italy
2016: World Hearing Center, Institute of Physiology and Pathology of Hearing, Warsaw,Poland
2015: Cochlear Science and Research Center Berlin Germany.
2014: Cochlear implant Center Medel Company Innsburck, Austria.
2014: Hannover Medical School. Clinic for Laryngology, Rhinology and Otology, Hannover, Germany
2014: Academy of Hearing Aid Acoustics (Akademie für Hörgerate-Akustik), Lübeck, Germany.
2013: International European Sialendoscopy Training Center, Geneva, Switzerland.
2012: University clinic of ORL, Head and Neck Surgery, klinikum der Universitat, Munchen, Germany.
2012: University clinic of ORL, Head and Neck Surgery, Bern, Switzerland.
2011: University clinic of ORL, Head and Neck Surgery, klinikum der Universitat, Munchen, Germany.
2007: The Ohio State University, Medical Faculty, Department of Otolaryngology, Division of Otology and Neurotology. Columbus, Ohio, USA.
2006: University of Würzburg, Department of Otolaryngology, Division of Otology and Neurotology. Würzburg, Germany.
1999-2003 İnönü Üniversitesi Tıp Fakültesi Kulak Burun Boğaz Anabilim Dalı
1993-1999 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi

Turkish Otorhinolaryngology and Head and Neck Surgery Association

Turkish Otorhinolaryngology and Head and Neck Surgery Foundation

Turkish Rhinology Society

Tigris-Euphrates Basin Otorhinolaryngology and Head and Neck Surgery Association

Gaziantep Otorhinolaryngology Association

Turkish Otorhinolaryngology and Head and Neck Surgery Qualification Board

Turkish Otology Association

Malatya Otorhinolaryngology Association

American Academy of Otolaryngology Head and Neck Surgery

Mediterranean Society of Otology and Audiology

International Vertigo Association

Assoc. Prof. Dr. Fatih Ceran is a plastic, reconstructive, and aesthetic surgeon. He trained at Sağlık Bilimleri University, Istanbul Bağcılar Training and Research Hospital from 2012 to 2017. He holds microsurgery and advanced microsurgery certificates from the Frankfurt Microsurgery Course in 2014, organized by the University of Louisville. He graduated first in his class from Selçuk University Faculty of Medicine (2005–2011).

Experience: He conducted experimental research at Bağcılar in 2014. He worked in plastic surgery at Batman Training and Research Hospital from 2017 to 2020. He then served at Batman Medicalpark Hospital from 2020 to 2022.

Publication: He published in the Journal of Craniofacial Surgery (2014;25(3):1078–81). Practice interests include rhinoplasty, breast aesthetics, liposuction, abdominoplasty, blepharoplasty, brow lift, facelift, fat injections, otoplasty, jaw and cheekbone surgery, and leg and genital aesthetics.

Experience

2019 - 2022

University of Health Sciences, Faculty of Medicine, Ankara City Hospital, Cardiology Clinic, Ankara

2017 - 2019

University of Health Sciences, Faculty of Medicine, Turkey Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2012 - 2017

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2012 - 2017

T.R. Karabük University, Faculty of Medicine, Department of Cardiology

2006 - 2006

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

2001 - 2006

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

1996 - 2001

Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,

Education

2017 Karabük University, Faculty of Medicine, Department of Cardiology

2006 Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic

2001 Türkiye Higher Specialization Training and Research Hospital, Ankara, Cardiology

1996 Ankara University, Faculty of Medicine

Dr. Ionuț Gobej is a board-certified pediatric neurosurgeon. He trained in France and practices in Romania. He focuses on minimally invasive brain and spine surgery. His expertise includes endoscopic transnasal procedures and Gamma Knife radiosurgery.

He treats children with brain tumors, congenital malformations, and vascular disorders. He also trains future neurosurgeons and helps develop modern, multidisciplinary care programs.

Dr. Thakoon Poonthananiwatkul is a surgeon. He specializes in bariatric, metabolic, and minimally invasive (laparoscopic) procedures. He has advanced training in weight-loss and metabolic surgery. He uses proven methods to improve health and quality of life for patients with obesity and related conditions.

He has years of surgical experience and international training. He provides safe, precise care. He offers support before, during, and after surgery. His care focuses on lasting weight control and better metabolic health.

Dr. Gabriel Crasmariu is an interventional cardiologist with advanced expertise in minimally invasive treatments for cardiovascular disease. He is a member of the Romanian Society of Cardiology and the European Society of Cardiology.

He performs coronary angiography and angioplasty with stent placement. His focus includes complex coronary artery disease, peripheral arterial disease, renal denervation, and TAVI. He also provides specialized heart failure assessments. He takes part in multidisciplinary decisions for patients who may need cardiac surgery.

EDUCATION:

2009

Ankara Etlik Maternity Hospital and Gynecology Education and Research Hospital, Gynecology and Obstetrics

2003

Ankara University, Faculty of Medicine

EXPERIENCE:

2019 - to present

Medipol University Pendik Hospital

2009 - 2019

Yakacık Maternity and Child Diseases Hospital

PUBLICATIONS:

Articles Published in Journals Indexed in SCI, SSCI and AHCI

Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial

YİĞİT E., ÜNSAL S.

Climacteric , 2024 (SCI-Expanded)

EDUCATION:

2014 ADNAN MENDERES UNIVERSITY FACULTY OF MEDICINE, CHILD HEALTH AND DISEASES, CHILD NEUROLOGY

2011 IZMIR EDUCATION AND RESEARCH HOSPITAL, CHILD HEALTH AND DISEASES

2011 Izmir Tepecik Education and Research Hospital, Child Health and Diseases

2004 DICLE UNIVERSITY, FACULTY OF MEDICINE

EXPERIENCE:

2018 Istanbul Medipol Hospital

2017 - 2018 Kartal Education and Research Hospital

2014 - 2016 Denizli State Hospital

2011 - 2014 Aydin Adnan Menderes University Faculty of Medicine Hospital

2006 - 2011 Izmir Tepecik Education and Research Hospital

2011Izmir Education and Research Hospital

Dr. Alper Karaoglan is a Professor of Neurosurgery at Memorial Bodrum Hospital. He has many years of experience in neurosurgery. He worked at Maltepe University Faculty of Medicine and Taksim Training and Research Hospital in Istanbul. Since 2008, he has held the positions of Professor, Associate Professor, and Assistant Professor in neurosurgery.

Dr. Karaoglan is a member of the Turkish Medical Association and the Turkish Neurosurgical Society. He has received several awards. These include the Best Paper Award at the Turkish Neurosurgical Society Scientific Congress in 2005 for his research on resveratrol’s protective effects after subarachnoid hemorrhage, and the Young Neurosurgeon Encouragement Award in 2008.

Thanet Narula. General Practitioner. (English, Thai Speaking). With on-going specialist training in Internal Medicine, Dr. Thanet is a skilled physician

Education

Honours Graduate, MD, Faculty of Medicine, MAHSA University, Malaysia, 2019

Certifications

Currently a Resident in Internal Medicine, Lerdsin Hospital Bangkok

Languages spoken: Thai and English

2002 – 2008 – Siriraj Medical School, Mahidol University

2008 – 2013 – Department of Internal Medicine, Rajavithi Hospital

2013 – 2015 – Department of Cardiology, Internal Medicine Rajavithi Hospital

2019 – 2020 – Cardiology Intervention, Department of Cardiology, Internal Medicine Rajavithi Hospital

Languages: English and Thai

Кәсіби тәжірибе

2006 жылдан бері Мадридтегі Quironsalud Университеттік Ауруханасының және Ruber Juan Bravo Ауруханасының Неврология бөлімінің бастығы болып қызмет атқарады.

Мадридтегі Еуропалық Университеттің Биомедициналық Ғылымдар факультетінің Медицина профессоры, Медицина Ғылымдары Профессорының ұлттық аккредитациясына ие (ANECA-дан берілген).

Медицина докторы, Мадридтегі Complutense университеті (UCM). Көрнекті докторлық диссертацияға арналған сыйақы (UCM, 2004): көптеген склерозда қоршаған орта факторы ретінде адамның герпес вирусы 6-мен байланысын зерттеу.

Ғылыми қоғамдарға мүшелік

Quironsalud Мадридтегі Нейроғылымдар бойынша ұлттық және халықаралық жетекші зерттеуші (маусым 2015 – қазіргі уақытқа дейін)

Мадридтегі Quironsalud Университеттік Ауруханасының Зерттеу Комитетінің Президенті (2012 жылдан қазіргі уақытқа дейін).

Сан-Карлос Клиникалық Ауруханасының Зерттеу Комитетінің мүшесі (2012-2015).

Мадридтегі Complutense университетінің Медицина факультетінің Кеңес мүшесі (2011-2015).

Зерттеу және оқыту

100 ұлттық және халықаралық клиникалық сынақтардың бас зерттеушісі.

Carlos III Денсаулық Институтының 7 FIS зерттеу жобасы (соңғы 5 бас зерттеуші ретінде).

Жеке қорлардан 10 жоба, бәсекеге қабілетті негізде алынған (7 бас зерттеуші ретінде).

Ол 949,917 жалпы әсер ету факторына және 4,552 сілтеме иеленген 139 халықаралық мақаланың авторы. H-факторы 34 (2018) болған 38 кітап пен кітап тараулары бар.

Оның басылымдары зерттеулерге ең ғаламдық әсер ететін журналдарда ерекшеленіп тұрады, мысалы, New England Journal of Medicine және Lancet.

Др. Рафаэль Арройо түрлі Конгрестерде 300-ден астам халықаралық және ұлттық баяндамалар жасаған.

Білім :

Мадридтегі Еуропалық Университеттің Биомедициналық Ғылымдар факультетінің Медицина профессоры және Медицина Ғылымдары Профессорының ұлттық аккредитациясына ие (ANECA-дан берілген).

Experience

On his return from London, he organized and directed the Arrhythmia Unit of the Cardiology Service of the University Hospital Nuestra Señora del Pino in Las Palmas until 2000.

He later became Deputy Director of the Arrhythmia Department and Director of the Electrophysiology Laboratory at the Jimenez Diaz Foundation in Madrid.

Professor of Cardiology at the Autonomous University and Director of the North American Society of Pacing and Electrophysiology (Heart Rhythm Society) Fellowship Program, positions he held for 6 years before moving to the Quironsalud University Hospital of Madrid in 2006.

Dr. Cabrera has been head of the cardiology department at the Quironsalud University Hospital of Madrid since its opening in 2006.

Since January 2013, he has also been Head of the Cardiology Department at the Ruber Juan Bravo Hospital Complex and, in 2022, Head of Service at the new Olimpia Center.

He is a professor at the European University of Madrid, where he heads the Department of Clinical and Fundamental Translational Cardiology.

Qualification

Doctorate in Medicine and Surgery from the Faculty of Medicine of the University of Granada. From 1994 to 1996 he completed postgraduate training as an interventional cardiologist in the Arrhythmia Unit (Cardiac Electrophysiology Laboratory) of the Jiménez Díaz Foundation in Madrid.

Senior Research Fellow. National Heart and Lung Institute. Royal Brompton. Paediatric Heart Morphology under the direction of Prof. Robert H. Anderson in London (UK) in 1997.

Research and Teaching

Member of the Spanish Society of Cardiology, SEC Arrhythmia Section, European Society of Cardiology, Arrhythmia Working Group, European Heart Rhythm Association, North American Society of Pacing and Electrophysiology.

He serves on numerous committees for the selection and monitoring of fellowships and research projects of various national and international cardiology and cardiac arrhythmia societies.

Reviewer of articles for publication in the most relevant journals in the specialty. Journal of the Spanish Society of Cardiology, Heart Rhythm, Journal of Cardiovascular Electrophysiology, PACE, Europace, Heart Circulation, Journal of the American College of Cardiology, Electrophysiology of Circulation, Journal of Interventional Cardiovascular Electrophysiology.

Member of the European Society of Cardiology

Member of the Arrhythmia Working Group

European Society of Cardiology

Member of the Arrhythmia Section of the Spanish Society of Cardiology.

Member of the European Society of Cardiology (FESC)

Member of the European Heart Rhythm Association.

Member of the Selection and Control Committee of the Spanish Society of Cardiology. Post-Residency Research Training Fellowships 2001-2002/2002-2003.

Evaluator and member of the selection committee for research, technological development and innovation projects of the Government of Extremadura. Ministry of Education, Science and Technology (2001-2004).

Member of the Spanish research group. Integrated Action Programme between Spain and the United Kingdom. Directorate General of Higher Education and Research (reference HB 1998-0030). Project title: Anatomical study of the cavities of the human heart and its application to clinical electrophysiology.

Member of the Spanish research group. Integrated Action Programme between Spain and Austria. Directorate General for Higher Education and Research (reference HU 1999-0002). Project title: Electromorphological analysis of the terminal crest and posterior pectineus muscle. Its importance as a morphological substrate in different types of supraventricular tachycardias.

Participation in the clinical commission and protocol of the study AZIMILIDE versus SOTALOL on programmed cardioversion in patients with atrial fibrillation. 2001-2003.

Experience

2018 - 2022

Health Sciences University – Şişli Hamidiye Etfal Training and Research Hospital

2016 - 2018

Diyarbakır Memorial Dicle Hospital Cardiology Clinic

2010 - 2010

Dicle University Faculty of Medicine, Department of Cardiology

2010 - 2016

Private Veni Vidi Hospital, Cardiology Clinic Supervisor

2006 - 2010

Dicle University Faculty of Medicine, Department of Cardiology

2005 - 2006

Urfa State Hospital

1999 - 2005

Turkey High Specialization Training and Research Hospital

1998 - 1999

Duruca Health Center

Education

2018

Health Sciences University, Cardiology

2010

Dicle University, Department of Cardiology

2005

Cardiology Turkey High Specialization Training and Research Hospital, Medical Specialization

1998

Ege University, Faculty of Medicine

Dr. Mustafa Emiroglu is a general surgery specialist at Memorial Bodrum Hospital. He has significant experience from his work at Sağlık Bilimleri University Tepecik SUAM (2016–2023) and Kırşehir Hospital (1997–1999).

He earned his medical degree from Istanbul University Cerrahpaşa Faculty of Medicine. He completed his specialization at Tepecik Training and Research Hospital. Dr. Emiroglu is a member of the Turkish Society of Surgery, the Endocrine Surgery Association, and the Colorectal Surgery Association.

He has attended advanced courses, including the Europe Senology Academia. He has also received training in proctologic, hemorrhoidal, and oncoplastic breast surgery, as well as thyroid diseases.